REPL Price / Book | REPLIMUNE GROUP, INC.

Replimune Group, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Replimune Group, Inc. price/book ratio for the quarter ending 2026-06-30 was 8.79, a 309.99% increase year-over-year.
Replimune Group, Inc. price/book ratio for the quarter ending 2026-03-31 was 3.81, a 110.71% increase year-over-year.
Replimune Group, Inc. price/book ratio for the quarter ending 2025-12-31 was 3.68, a 90.16% increase year-over-year.
Replimune Group, Inc. price/book ratio for the quarter ending 2025-09-30 was 1.24, a 36.67% decline year-over-year.
Replimune Group, Inc. price/book ratio for fiscal 2026 was 8.79.
Replimune Group, Inc. price/book ratio for fiscal 2025 was 3.68, a 90.16% increase from fiscal 2024.
Replimune Group, Inc. price/book ratio for fiscal 2024 was 1.93, a 57.48% increase from fiscal 2023.
Replimune Group, Inc. price/book ratio for fiscal 2023 was 1.23, a 52.55% decline from fiscal 2022.

Available history: 2018-09-30 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	8.79	$928.81M	$105.65M
2026-03-31	3.81	$632.78M	$166.16M
2025-12-31	3.68	$774.01M	$210.54M
2025-09-30	1.24	$327.73M	$263.34M
2025-06-30	2.14	$722.05M	$336.72M
2025-03-31	1.81	$751.58M	$415.84M
2024-12-31	1.93	$932.58M	$482.37M
2024-09-30	1.97	$749.6M	$381.46M
2024-06-30	1.44	$614.79M	$426.45M
2024-03-31	1.34	$501.76M	$374.51M
2023-12-31	1.23	$517.5M	$421.54M
2023-09-30	2.17	$1.01B	$465.17M
2023-06-30	2.66	$1.37B	$514.03M
2023-03-31	1.8	$1B	$555.29M
2022-12-31	2.59	$1.54B	$595.35M
2022-09-30	2.24	$859M	$384.07M
2022-06-30	2.1	$861.74M	$410.26M
2022-03-31	1.95	$803.81M	$411.23M
2021-12-31	2.92	$1.28B	$437.51M
2021-09-30	3.04	$1.39B	$457.41M
2021-06-30	3.75	$1.8B	$479.02M
2021-03-31	2.85	$1.42B	$498.73M
2020-12-31	3.43	$1.77B	$516.2M
2020-09-30	3.55	$927.99M	$261.39M
2020-06-30	3.6	$1B	$277.81M
2020-03-31	1.99	$365.59M	$183.72M
2019-12-31	2.66	$525.87M	$197.57M
2019-09-30	3.65	$440.9M	$120.64M
2019-06-30	3.57	$464.19M	$130.15M
2019-03-31	3.5	$481.82M	$137.86M
2018-12-31	2.21	$316.41M	$143.24M
2018-09-30	3.39	$508.01M	$150.04M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	8.79	$928.81M	$105.65M
2025-12-31	3.68	$774.01M	$210.54M
2024-12-31	1.93	$932.58M	$482.37M
2023-12-31	1.23	$517.5M	$421.54M
2022-12-31	2.59	$1.54B	$595.35M
2021-12-31	2.92	$1.28B	$437.51M
2020-12-31	3.43	$1.77B	$516.2M
2019-12-31	2.66	$525.87M	$197.57M
2018-12-31	2.21	$316.41M	$143.24M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Vor Biopharma Inc. (VOR)	United States	$1.091B	1.60
MeiraGTx Holdings plc (MGTX)	United States	$1.061B	16.10
Monte Rosa Therapeutics, Inc. (GLUE)	United States	$1.002B	-12.81
Cullinan Therapeutics, Inc. (CGEM)	United States	$0.993B	-5.72
Odyssey Therapeutics, Inc. (ODTX)	United States	$0.960B
Maze Therapeutics, Inc. (MAZE)	United States	$1.457B	-12.40
Inhibrx Biosciences, Inc. (INBX)	United States	$1.477B	-10.08
Sana Biotechnology, Inc. (SANA)	United States	$0.886B	-4.92
Candel Therapeutics, Inc. (CADL)	United States	$0.885B	-8.86
Attovia Therapeutics, Inc. (ATTO)	United States	$0.828B